Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13786730 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL18673137 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13618856 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL24222481 | 0.77 | — | — | |
| SCHEMBL14507573 | 0.77 | — | — | |
| SCHEMBL13667747 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL17643537 | 0.75 | — | — | |
| SCHEMBL12516261 | 0.74 | — | — | |
| SCHEMBL13875736 | 0.74 | — | — | |
| SCHEMBL14292189 | 0.72 | HTT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2009135700-A1 | BLEACHING AGENT HAVING CATIONIC ACYL PYRIDINIUM DERIVATIVES, CO-BLEACHING ACTIVATORS, AND HYDROGEN PEROXIDE | HENKEL AG & CO. KGAA (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2005120515-A2 | NOVEL SULFONAMIDES AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |